Ozempic first dose: what 3 hours tells you (and what it doesn't)

What did @mynewme010 actually say?

The creator posted about their first day on semaglutide at the 0.25mg starting dose, noting that three hours after their injection they had experienced no side effects. They also mentioned their doctor drew blood to check cholesterol and other markers before or alongside starting treatment. The caption hashtags suggest this is part of a weight loss journey, with #misikurus (Malay for "slim mission") indicating the purpose is body weight management.

The transcript itself appears to be in a language that did not render clearly, so this analysis is based primarily on the caption, which is detailed enough to work with. The key claims are: (1) 0.25mg is their starting dose, (2) no side effects after three hours, and (3) baseline blood work including cholesterol was taken.

Does the science back this up?

Largely, yes, though the "no side effects at three hours" framing deserves some scrutiny. The 0.25mg starting dose is exactly what the clinical protocol calls for, and baseline metabolic panels before starting a GLP-1 are standard good practice. But three hours is too early to declare a clean side effect window.

The SUSTAIN-1 trial (Sorli et al., 2017, The Lancet Diabetes and Endocrinology) established that semaglutide's most common adverse effects, primarily nausea, vomiting, and diarrhea, tend to peak in the first few weeks of dose escalation, not necessarily within hours of a single injection. Semaglutide has a half-life of approximately one week, so plasma concentrations build gradually. The first real wave of GI distress often hits 6 to 24 hours post-injection or even a few days later, particularly with the first dose. Three hours of comfort does not mean the side effect window has passed.

What did they get wrong (or right)?

They got the dose right. The 0.25mg starting dose is the FDA-approved and clinically recommended initiation dose for semaglutide, used for the first four weeks before escalating to 0.5mg. Starting here is not optional, it is specifically designed to reduce GI burden during the body's adaptation period. Credit where it is due: this person is following a supervised protocol with a doctor, not self-dosing from an unregulated source.

What they got slightly wrong, or at least framed imprecisely, is implying that three hours without symptoms means the first dose went smoothly. That is premature. A review by Davies et al. (2021, Diabetes, Obesity and Metabolism) noted that nausea from semaglutide is dose-dependent and can manifest well beyond the immediate post-injection period. Declaring victory at the three-hour mark is like leaving a concert after the opening act and saying it was a quiet night.

The baseline cholesterol check is actually a smart move and often skipped in casual or unsupervised GLP-1 use. Research has shown semaglutide can modestly improve LDL and triglyceride profiles (Husain et al., 2019, NEJM), so having a baseline makes clinical tracking meaningful.

What should you actually know?

If you are starting semaglutide, the first four weeks at 0.25mg are a titration phase, not a full therapeutic dose. You are not going to see significant weight loss results at this level. The point is to let your GI tract adapt before escalating. Do not interpret a lack of dramatic early results as treatment failure.

Side effects at this stage are common and often temporary. In the STEP-1 trial (Wilding et al., 2021, NEJM), about 44% of participants on semaglutide 2.4mg reported nausea, but discontinuation due to adverse effects was relatively low at around 7%. The side effect profile at 0.25mg is considerably milder than at the therapeutic 1mg or 2.4mg doses, but it is not zero.

The blood work this creator's doctor ordered is genuinely good clinical practice. A baseline metabolic panel including HbA1c, lipids, kidney function, and liver enzymes allows a prescriber to monitor not just side effects but also the metabolic improvements that semaglutide is expected to produce over time. Anyone starting a GLP-1 without this baseline is missing important data.

• Do not assume side-effect-free hours mean a side-effect-free experience overall.
• 0.25mg is a titration dose, not a therapeutic target.
• Baseline blood work is a marker of responsible prescribing, not just routine paperwork.
• Nausea and GI symptoms, if they occur, typically ease after the first few weeks for most patients.